Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single Center, Dose Escalation Study of the Safety and Pharmacokinetics of dMAb AZD5396 and dMAb AZD8076 Delivered as dMAbs in Healthy Adults

Next Previous
Trial Profile

A Phase 1, Open-Label, Single Center, Dose Escalation Study of the Safety and Pharmacokinetics of dMAb AZD5396 and dMAb AZD8076 Delivered as dMAbs in Healthy Adults

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 5396 (Primary) ; AZD 8076 (Primary) ; Hyaluronidase; Methylprednisolone
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept

Most Recent Events

  • 18 Mar 2025 According to an Inovio Pharmaceuticals Media Release, company anticipates additional data to be presented at upcoming scientic conferences and published in a peer-reviewed journal.
  • 18 Mar 2025 According to an Inovio Pharmaceuticals Media Release, trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and the University of Pennsylvania and funded by the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Oce for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
  • 13 Mar 2025 interim results presented in the Inovio Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top